Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - piroxicam 20 mg - comprimé - 20 mg - piroxicam 20 mg - piroxicam

Portugalska - portugalščina - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - piroxicam - comprimido - 20 mg - piroxicam 20 mg - piroxicam - genérico - duração do tratamento: curta ou média duração

Portugalska - portugalščina - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - piroxicam - comprimido - 20 mg - piroxicam 20 mg - piroxicam - genérico - duração do tratamento: curta ou média duração

Portugalska - portugalščina - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - piroxicam - comprimido - 20 mg - piroxicam 20 mg - piroxicam - genérico - duração do tratamento: curta ou média duração

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physician therapeutics llc - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 20 mg - indications and usage carefully consider the potential benefits and risks of piroxicam and other treatment options before deciding to use piroxicam. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). piroxicam is indicated: • for relief of the signs and symptoms of osteoarthritis. • for relief of the signs and symptoms of rheumatoid arthritis. contraindications piroxicam is contraindicated in patients with known hypersensitivity to piroxicam. piroxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precautions: preexisting asthma). piroxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings). pediatric use safety and effect

Združene države Amerike - angleščina - NLM (National Library of Medicine)

proficient rx lp - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam capsules, usp are indicated: piroxicam capsules are contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting at 30 weeks gestation. risk summary use of nsaids, including piroxicam capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxicam capsules, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of piroxicam capsules in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss. in animal reproduction studies in rats and rabbits, there was no evidence of teratogenicity at expo

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam capsules are indicated: piroxicam capsules are contraindicated in the following patients: use of nsaids, including piroxicam capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxicam capsules, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of piroxicam capsules in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. in animal reproduction studies in rats and rabbits, there was no evidence of teratogenicity at exposures up to 5 and 10 times the maximum recommended human dose (mrhd), respectively. in rat studies with

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam capsules are indicated: piroxicam capsules are contraindicated in the following patients: use of nsaids, including piroxicam capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxicam capsules, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of piroxicam capsules in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. in animal reproduction studies in rats and rabbits, there was no evidence of teratogenicity at exposures up to 5 and 10 times the maximum recommended human dose (mrhd), respectively. in rat studies with

Združene države Amerike - angleščina - NLM (National Library of Medicine)

direct_rx - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam capsules are indicated: for relief of the signs and symptoms of osteoarthritis. for relief of the signs and symptoms of rheumatoid arthritis. piroxicam capsules are contraindicated in the following patients: known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to piroxicam or any components of the drug product [see warnings and precautions (5.7, 5.9)] history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] in the setting of cabg surgery [see warnings and precautions (5.1)] 8.1 pregnancy risk summary use of nsaids, including piroxicam capsules, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of piroxicam capsules use betwe

Združene države Amerike - angleščina - NLM (National Library of Medicine)

zydus lifesciences limited - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam capsules, usp are indicated: - for relief of the signs and symptoms of osteoarthritis. - for relief of the signs and symptoms of rheumatoid arthritis. piroxicam is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to piroxicam or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1 )] pregnancy category c prior to 30 weeks gestation; category d starting at 30 weeks gestation. risk summary use of nsaids, including piroxicam, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including